Fyteko and Janssen PMP announce collaboration agreement for NURSPRAY®

Fyteko and Janssen PMP announce collaboration agreement for NURSPRAY®

The agri-biomolecule developer Fyteko has announced a new collaboration agreement with JANSSEN PMP, a division of Janssen Pharmaceutica NV, for development of its novel crop biostimulant.

Fyteko and Janssen PMP have signed an Exclusive Agreement to evaluate the commercial potential of Nurspray® in agricultural regions around the world where Janssen PMP has a solid footprint. Fyteko has granted Janssen PMP the right to use Nurspray® intellectual property for evaluation and demonstration purposes. Under the agreement, Janssen PMP will perform field demonstrations and early market development activities necessary for commercialization. Fyteko continues to conduct field trials, R&D and regulatory development concurrently in other regions, collaborating with various companies.

NURSPRAY® has been in development at Fyteko since 2014, when the company’s founders discovered hydroxycinnamic acid oligomers’ role as the crucial ‘signal’ molecule in plants’ natural defence mechanism against abiotic stress. Fyteko's sustainable solution has shown consistent efficacy in many regions and multiple crops, covering many environmental and soil conditions, over several years.

“Application of the biomolecule raises crop yields, but we also saw other improvements” says the company’s co-founder and CEO Guillaume Wegria, “field trials show impressive robustness and dispel any remaining concerns about the ability of bioproducts to stand their ground against conventional products,” he says.

“The strategic move to have such an innovative and effective biostimulant in our portfolio is a natural step forward for us” says Geoffroy de Chabot-Tramecourt, Head of R&D and Business Development at Janssen PMP. “Improving the quality and yield of fresh produce by applying technologies derived from nature is our priority”

About Janssen PMP
Janssen PMP is a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.

Janssen PMP is a long-established world leader in the development and formulation of new and highly effective active substances and end-use products for the protection of materials and food, especially fruits and vegetables. With more than 50 years’ experience in Post-Harvest treatments and Plant Protection, Janssen PMP has developed strong technical and commercial expertise. Through protection of our surroundings, we aim to protect the health and well-being of the people in the environment in which our products are being used.

Geoffroy de Chabot-Tramecourt, Director R&D and Business Development
Turnhoutseweg 30, 2340 Beerse, Belgium
Tel: +32 14 60 28 57
Mobile: +32 471 80 82 09

About Fyteko
Fyteko believes in a more sustainable agriculture. Inspired with original research, they are making it happen. Founded in 2014, the Brussels-based AgTech company is focusing on the creation of a bio-based input economy for agriculture. Its advanced crop biostimulants emulate solutions that already exist in nature. The company believes this offers the best approach to the common problems and threats facing global crop production, as well as consciously aligning itself with the growing consensus that agricultural is in transition to a lower-input, sustainable model that delivers productivity without compromising environmental performance.

As its development pipeline speeds up, Fyteko aims to build a standout portfolio, entirely biological, of relevance to the world’s major crop-producing regions: Europe, USA, Latin America, Ukraine and Africa.

Denis Payen, Head of Sales
Allée de la recherche 4, 1070 Brussels, Belgium
Tel: +32 23 72 04 09
Mobile: +32 477 47 23 38